Digitalis Ventures — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Matchpoint TherapeuticsinOct 2022
Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
BiotechCambridge, US
Andre Turenne(Executive Officer, Director)in
BoardJason Hafler(Director)inBruce Booth(Director)Daniel Becker(Director)
Co-investorsAccess BiotechnologySanofi Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.